Zenotech Laboratories Ltd
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
- Market Cap ₹ 465 Cr.
- Current Price ₹ 76.2
- High / Low ₹ 108 / 52.2
- Stock P/E 79.0
- Book Value ₹ 15.3
- Dividend Yield 0.00 %
- ROCE 12.9 %
- ROE 9.64 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 36.0% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.04 | 2.75 | 4.08 | 2.06 | 2.25 | 11.14 | 13.03 | 26.02 | 22.45 | 36.57 | 42.42 | 40.83 | 39.73 | |
23.51 | 19.75 | 24.14 | 9.73 | 12.65 | 19.01 | 16.54 | 17.04 | 16.07 | 19.11 | 21.71 | 23.56 | 25.84 | |
Operating Profit | -20.47 | -17.00 | -20.06 | -7.67 | -10.40 | -7.87 | -3.51 | 8.98 | 6.38 | 17.46 | 20.71 | 17.27 | 13.89 |
OPM % | -673.36% | -618.18% | -491.67% | -372.33% | -462.22% | -70.65% | -26.94% | 34.51% | 28.42% | 47.74% | 48.82% | 42.30% | 34.96% |
-0.07 | 2.39 | 0.35 | 0.04 | 1.91 | 2.37 | 4.71 | 7.54 | 0.41 | 0.63 | 1.08 | 0.96 | 2.64 | |
Interest | 1.47 | 4.69 | 6.65 | 7.55 | 7.50 | 2.45 | 0.12 | 0.89 | 1.55 | 1.22 | 0.11 | 0.00 | 0.00 |
Depreciation | 3.52 | 3.56 | 4.06 | 3.96 | 3.87 | 3.90 | 4.20 | 4.85 | 6.46 | 6.97 | 7.17 | 7.09 | 6.95 |
Profit before tax | -25.53 | -22.86 | -30.42 | -19.14 | -19.86 | -11.85 | -3.12 | 10.78 | -1.22 | 9.90 | 14.51 | 11.14 | 9.58 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -123.94% | 20.12% | 25.49% | |
-25.52 | -22.86 | -30.41 | -19.14 | -19.87 | -11.85 | -3.13 | 10.78 | -1.22 | 22.18 | 11.59 | 8.30 | 6.66 | |
EPS in Rs | -4.18 | -3.75 | -4.99 | -3.14 | -3.26 | -1.94 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.36 | 1.09 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 31% |
5 Years: | 26% |
3 Years: | 22% |
TTM: | -2% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 36% |
3 Years: | 107% |
TTM: | -37% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 23% |
3 Years: | 25% |
1 Year: | 16% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 19% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 34.43 | 34.43 | 34.43 | 34.43 | 34.43 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 |
Reserves | -8.31 | -31.17 | -61.68 | -80.49 | -100.33 | -19.01 | -22.13 | -11.40 | -12.62 | 9.61 | 21.24 | 29.51 | 32.13 |
16.22 | 46.92 | 54.32 | 54.29 | 54.28 | 0.00 | 20.24 | 21.42 | 20.66 | 6.00 | 0.00 | 0.00 | 0.00 | |
24.65 | 20.01 | 36.64 | 44.69 | 62.37 | 39.72 | 25.45 | 14.51 | 16.78 | 17.45 | 18.61 | 15.66 | 14.76 | |
Total Liabilities | 66.99 | 70.19 | 63.71 | 52.92 | 50.75 | 81.74 | 84.59 | 85.56 | 85.85 | 94.09 | 100.88 | 106.20 | 107.92 |
58.89 | 56.25 | 52.13 | 48.17 | 46.83 | 44.43 | 43.11 | 48.73 | 74.23 | 70.91 | 65.38 | 65.58 | 63.05 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.32 | 16.95 | 29.08 | 2.18 | 0.28 | 4.98 | 1.96 | 2.77 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
8.10 | 13.94 | 11.58 | 4.75 | 3.92 | 34.99 | 24.53 | 7.75 | 9.44 | 22.90 | 30.52 | 38.66 | 42.10 | |
Total Assets | 66.99 | 70.19 | 63.71 | 52.92 | 50.75 | 81.74 | 84.59 | 85.56 | 85.85 | 94.09 | 100.88 | 106.20 | 107.92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-9.81 | -24.30 | -7.72 | -4.80 | 1.64 | -16.25 | -14.04 | 11.38 | 5.74 | 17.67 | 20.66 | 11.82 | |
-0.44 | -0.50 | 0.34 | 5.50 | -0.69 | -2.65 | -16.19 | -20.79 | -4.82 | -1.84 | -5.82 | -21.15 | |
10.10 | 29.63 | 6.77 | -0.83 | -0.72 | 46.83 | 15.02 | -2.70 | 0.45 | -15.87 | -6.11 | 0.00 | |
Net Cash Flow | -0.15 | 4.83 | -0.60 | -0.13 | 0.23 | 27.92 | -15.21 | -12.11 | 1.38 | -0.04 | 8.73 | -9.33 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 8.40 | 11.95 | 35.78 | 62.01 | 0.00 | 0.00 | 66.11 | 26.09 | 61.78 | 39.22 | 28.57 | 29.05 |
Inventory Days | 375.23 | 562.10 | 232.69 | 305.45 | 202.29 | 374.12 | 294.03 | |||||
Days Payable | 731.71 | 487.64 | 222.42 | 816.45 | 1,127.98 | 2,468.31 | 2,088.61 | |||||
Cash Conversion Cycle | -348.07 | 86.41 | 46.05 | -448.99 | -925.69 | -2,094.19 | -1,728.47 | 26.09 | 61.78 | 39.22 | 28.57 | 29.05 |
Working Capital Days | -2,916.40 | -2,416.96 | -3,294.84 | -8,061.89 | -10,395.20 | -1,218.52 | -537.00 | -171.00 | -163.56 | -106.00 | -98.86 | -62.93 |
ROCE % | -48.07% | -39.28% | -61.54% | -65.67% | -61.84% | -5.93% | 8.14% | 0.47% | 15.26% | 18.35% | 12.94% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Oct - Copies of Advertisement published today i.e. October 24, 2024 for the extracts of Unaudited Financial Results of the Company for the quarter and half year …
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024 And Appointment Of Dr. Sachin Laxmanappa Gavandare As Chief Executive Officer (Key Managerial Personnel) Of The Company With Immediate Effect.
23 Oct - Approval of financial results and appointment of new CEO.
-
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024
23 Oct - Appointment of Dr. Sachin Gavandare as CEO and Q2 results.
-
Board Meeting Intimation for Consideration And Approval Of Financial Results
17 Oct - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products